A Clinical Trial Evaluating the Tolerability, Safety, and Preliminary Efficacy of NRG-103 Injection in Patients With Recurrent or Progressive High-grade Glioma

Clinical trial NCT07710690 · RECRUITING

Trial details

NCT number: NCT07710690
Sponsor: Neuregen Therapeutics Co., Ltd.
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

HGG High Grade Glioma (III or IV)High Grade Glioma

Start date: 2026-07-09
Primary completion: 2030-04-30
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.